Medical Management of Opioid Use Disorder | June 23, 2026
Date of Presentation: June 23, 2026
Type: Past Presentation Training
Audience: Clinical
Program: Ending the Epidemics in Indian Country ECHO Program
Keywords: #fentanyl #medications for opioid use disorder #methamphetamine #MOUD #risk reduction #Screening #substance use disorder #SUD #SUD treatment
In this presentation Jessica Gregg, PhD, MD and Jonathan Robbins, MD, briefly review FDA approved medications to treat opioid use disorder, discuss the fentanyl crisis and lastly cover how to understand buprenorphine and methods for starting the medication.
Recording:
Presented by:
Dr. Jonathan Leserman Robbins
Faculty
Jonathan Leserman Robbins, MD, MS, is a general internist and primary care doctor at Oregon Health & Science University in Portland, OR. He splits his time between outpatient primary care, the inpatient addiction consult service, and a pain and addiction consult clinic. He is an active educator and participates in several ECHOs on pain and addiction.
Read the full bio …
Dr. Jessica Gregg
Lead Faculty
Jessica Gregg, MD, PhD, received her undergraduate degree at Stanford University, her medical degree at the University of New Mexico, and a PhD in Medical Anthropology at Emory University. She began her medical career in primary care at Oregon Health and Science University (OHSU), where she co-founded the OHSU Department of Medicine’s Social Medicine curriculum in partnership with City Central Concern, a non-profit caring for individuals struggling with lack of housing and substance use disorders. She subsequently became the medical director for Central City Concern’s Hooper Detoxification and Stabilization Center, and eventually assumed the role of Senior Medical Director for Substance Use Disorder Services for the agency. She subsequently developed the HRBR clinic at OHSU, a low-threshold buprenorphine clinic, and in 2021, she became Chief Medical Officer for Fora Health in Portland, Oregon.
Read the full bio …Resources Provided:
Date added: June 26, 2026



















































































